

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1167)

**POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON JUNE 5, 2026**

At the Annual General Meeting (the “**AGM**”) of JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “**Company**”) held on June 5, 2026, all the proposed resolutions as set out in the notice of the AGM dated April 27, 2026 were voted by way of poll. Unless the content otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Company’s circular dated April 27, 2026 (the “**Circular**”).

The Company’s branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.

As at the date of the AGM, the total number of issued Shares of the Company was 791,755,080 Shares of US\$0.0001 each, including 8,029,800 treasury shares held by the Company. The treasury shares were excluded from the total number of issued Shares entitling the holder to attend and vote on the proposed resolutions at the AGM and the Company has not exercised the voting rights of the treasury shares at the AGM. There were no Shares repurchased by the Company which are pending for cancellation and should be excluded from the total number of shares of the Company in issue for the purpose of the AGM. Accordingly, the total number of Shares entitling the holders to attend and vote at the AGM was 783,725,280 Shares.

There were no restrictions on any Shareholders to cast votes on any of the proposed resolutions at the AGM. Save as above, no Shareholders were required to abstain from voting on any of the proposed resolutions at the AGM under the Listing Rules. There were no Shares entitling the holders to attend the AGM and abstain from voting in favor of any of the proposed resolutions at the AGM under Rule 13.40 of the Listing Rules. No Shareholders had stated their intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions at the AGM.

The poll results in respect of all the resolutions proposed at the AGM are as follows:

ORDINARY RESOLUTIONS		NO. OF VOTES (%)	
		FOR	AGAINST
1.	To receive and adopt the audited consolidated financial statements and the reports of the directors of the Company (the “ Directors ”) and auditor for the year ended December 31, 2025.	314,782,381 (100.000%)	0 (0.000%)
2.	(i) To re-elect Dr. Yinxiang WANG as an executive Director.	313,126,070 (99.474%)	1,656,311 (0.526%)
	(ii) To re-elect Dr. Te-li CHEN as a non-executive Director.	309,334,991 (98.426%)	4,947,390 (1.574%)
	(iii) To re-elect Dr. Ruilin SONG as an independent non-executive Director.	308,376,908 (98.121%)	5,905,473 (1.879%)
	(iv) To authorize the board (the “ Board ”) of Directors to fix the remuneration of the Directors.	314,218,781 (99.980%)	63,600 (0.020%)
3.	To re-appoint Deloitte Touche Tohmatsu as the auditor of the Company and to authorize the Board to fix its remuneration.	298,672,243 (95.033%)	15,610,138 (4.967%)
4.	To grant a general mandate to the Directors to allot, issue and deal with new shares of the Company (including any sale or transfer of the treasury shares of the Company) not exceeding 20% of the total number of issued shares of the Company (excluding treasury shares).*	296,763,263 (94.426%)	17,519,118 (5.574%)
5.	To grant a general mandate to the Directors to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company (excluding treasury shares).*	314,282,381 (100.000%)	0 (0.000%)
6.	To extend the general mandate to issue new shares by adding the number of shares repurchased.*	297,128,663 (94.542%)	17,153,718 (5.458%)

* The full text of resolutions numbered 4 to 6 are set out in the notice of AGM dated April 27, 2026.

Notes:

1. As more than 50% of votes were cast in favor of each of the above ordinary resolutions numbered 1 to 6, all of them were duly passed as ordinary resolutions of the Company.
2. All Directors attended the AGM in person or by electronic means.

By order of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, June 5, 2026

As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Dr. Te-li CHEN as non-executive Director, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.